Ilkos was a private biopharmaceutical company created by CTI and based in Montreal, Canada. The company licensed an deprioritized asset from Servier and developed it for the treatment of venous lower limb ulcers. The asset completed Phase 1 development with positive results and was ready to advance into late-stage clincial development
Lower limber ulcer
CTI LSF II
Lead
Director & Observer
August 25, 2016
Liquidated in 2020
Series A
Ilkos had access to a high potential asset from Servier that was ready for Phase 2 development that could lead to an early transaction if the Phase 2 data was positive
September 28, 2016
